-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Idiopathic osteoporosis (IOP) in premenopausal women is a rare disease
.
The affected women have complete gonadal function and no known secondary causes of bone loss or fragility
Osteoporosis
We recently reported that in premenopausal IOP, the bone anabolic drug Teriparatide significantly increases facial bone density through dual-energy X-ray absorption (DXA) of the spine and hip
.
Compared with placebo, the BFR/BS of the inner surface of the cancellous bone and cortex of the tetracycline-labeled transitional bone biopsy for three months increased significantly, which was biochemically reflected in the increase in serum formation markers
statistics
In postmenopausal women and men, unless anti-absorption therapy is given, the effect of teriparatide on bone density will disappear after stopping the drug
.
In contrast, postmenopausal women switched to denosumab two years after menopause, and bone density continued to increase
We previously reported 15 premenopausal women with idiopathic osteoporosis.
They completed the previous pilot study.
Two years after completing the study, the bone mineral density of the spine decreased significantly (4.
8%), despite the total hip (TH) and The decline of the femoral neck (FN) was small and not statistically significant
.
Therefore, for women who have completed this new 24-month study, we conducted a pre-planned extension study to evaluate the effects of taking 60 mg of denosumab every 6 months on bone mass.
method
This is an observational, non-randomized, prospective, open-label Phase 2b study to prevent bone loss in premenopausal women with idiopathic osteoporosis after drug withdrawal
.
If a premenopausal woman with idiopathic osteoporosis is one of 41 women who have participated in R01FD003902 (Idiopathic Osteoporosis of Idiopathic Premenopausal Women with Osteoporosis), and are in two If one of the study sites has received treatment for idiopathic osteoporosis for at least 12 months (n=40) and up to 24 months (n=35), they are eligible
prevention
Results: 32 cases in the 12m group, 29 cases in the 24m group, Ls5.
2±2.
6% and 6.
9±2.
6%, TH (2.
9±2.
4% and 4.
6±2.
8%), FN (3.
0±3.
8% and 4.
7±4.
9%)
.
During the treatment with 24M drug and 24M monoclonal antibody, the bone mineral density of LS, TH and FN increased by 21.
In summary, this study confirmed that in premenopausal women with idiopathic osteoporosis, the combination of teriparatide and denosumab is associated with a significant improvement in spine and hip bone mineral density
.
The microstructure of the trabecular bone of the TBS spine is improved
Source: Shane E, Shiau S, Recker RR, Denosumab After Teriparatide in Premenopausal Women with Idiopathic Osteoporosis, J Clin Endocrinol Metab 2021 Nov 24
Shane E, Shiau S, Recker RR, Denosumab After Teriparatide in Premenopausal Women with Idiopathic Osteoporosis, J Clin Endocrinol Metab 2021 Nov 24
Leave a message here
